Primary hyperparathyroidism in multiple endocrine neoplasia type 1: When to perform surgery?

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 141-144

  Giusti, Francesca ^a   Tonelli, Francesco ^a   Brandi, Maria Luisa ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Multiple endocrine neoplasia 1; PHPT MEN1; Primary hyperparathyroidism; Subtotal parathyroidectomy; Total parathyroidectomy

Indexed keywords

GENETICS; HUMAN; METHODOLOGY; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; PARATHYROID TUMOR; PARATHYROIDECTOMY; PEDIGREE; PRIMARY HYPERPARATHYROIDISM; REVIEW; THYMECTOMY;

GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; PEDIGREE; THYMECTOMY;

EID: 84863913804     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)23     Document Type: Review

References (39)

1. Carling T, Udelsman R. Parathyroid tumors. Curr Treat Options Oncol. 2003;4(4):319-28.
2. Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17(Suppl 2):N37-N43.
3. Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T, et al. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009;11(12):825-35.
4. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658-71.
5. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol. 2005;17(1):7-12.
6. Brandi ML, Bordi C, Tonelli F, Falchetti A, Marx SJ. Multiple endocrine neoplasia type 1. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology. 3. Vol. 2. San Diego, CA, USA: Academic Press; 2008;pp.1345-74.
7. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404-7.
8. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet. 1997;6(7): 1177-83.
9. Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol. 2001;15(10):1653-64.
10. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321-5.
11. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103(8):15558-63.
12. Pieterman CR, Vriens MR, Dreijerink KM, van der Luijt RB, Valk GD. Care for patients with multiple endocrine neoplasia type 1: the current evidence base. Fam Cancer. 2011;10(1):157-71.
13. Falchetti A, Marini F, Giusti F, Cavalli L, Cavalli T, Brandi ML. DNAbased test: when and why to apply it to primary hyperparathyroidism clinical phenotypes. J Intern Med. 2009;266(1):69-83.
14. Falchetti A, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2005. Available at: http://www.genetests.org. Accessed August 2005.
15. Falchetti A, Cilotti A, Vaggelli L, Masi L, Amedei A, Cioppi F, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab. 2008;4(6):351-7.
16. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of Cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol. 2010;2010:906163.
17. Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, et al. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. Clin Endocrinol (Oxf). 2008;69(5):756-62.
18. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple neoplasia type 1? Ann Surg. 2007;246(6):1075-82.
19. Wautot V, Vercherat C, Lespinasse J, Chambe B, Lenoir GM, Zhang CX, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat. 2002;20(1):35-47.
20. Carling T. Molecular pathology of parathyroid tumors. Trends Endocrinol Metab. 2001;12(2):53-8.
21. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005;257(1):27-37.
22. Wang CA. The anatomic basis of parathyroid surgery. Ann Surg. 1976;183(3):271-5.
23. Akerstrom G, Malmaeus J, Bergstrom R. Surgical anatomy of human parathyroid glands. Surgery. 1984;95:14-21.
24. Stalberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg. 2009;33(11):2234-43.
25. Marx SJ. Multiple endocrine neoplasia type 1. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001pp.943-66.
26. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69(1):1-19.
27. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism and response to parathyroidectomy. Arch Surg. 1999;134(10):1119-23.
28. Lourenço DMJr, Toledo RA, Mackowiak II, Coutinho FL, Cavalcanti MG, Correia-Deur JE, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features and bone mineral density profile. Eur J Endocrinol. 2008;159(3):259-74.
29. Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, et al. Sporadic and MEN 1 related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24(8):1404-10.
30. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80(3):723-8.
31. Dempster DW, Müller R, Zhou H, Kohler T, Shane E, Parisien M, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41(1):19-24.
32. Salmeron MD, Gonzalez JM, Sancho Insenser J, Goday A, Perez NM, Zambudio AR, et al. Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1. World J Surg. 2010;34(6):1325-31.
33. Schreinemakers JM, Pieterman CR, Scholten A, Vriens MR, Valk GD, Borel Rinkes IH. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg. 2011;35(9):1993-2005.
34. Waldmann J, López CL, Langer P, Rothmund M, Bartsch DK. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br J Surg. 2010;97(10):1528-34.
35. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247(3):501-10.
36. Chudek J, Piecha G, Nieszporek T, Marini F, Brandi ML, Wiecek A. Novel 1113delC menin gene mutation in a Polish family with multiple endocrine neoplasia type 1 syndrome. Eur J Intern Med. 2006;17(6):447-9.
37. Benson L, Ljunghall S, Akerström G, Oberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am J Med. 1987;82(4):731-7.
38. Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33-9.
39. Lourenço DM Jr, Coutinho FL, Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010;25(11):2382-91.